Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19

Mostrar otras versiones (1)

In the early phases of the COVID-19 pandemic, drug repurposing was widely used to identify compounds that could improve the prognosis of symptomatic patients infected by SARS-CoV-2. Hydroxychloroquine (HCQ) was one of the first drugs used to treat COVID-19 due to its supposed capacity of inhibiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Sala, Luca, Leonov, Vladislav, Mura, Manuela, Giannetti, Federica, Khudiakov, Aleksandr, Moretti, Alessandra, Crotti, Lia, Gnecchi, Massimiliano, Schwartz, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829511/
https://www.ncbi.nlm.nih.gov/pubmed/35153806
http://dx.doi.org/10.3389/fphys.2021.730127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829511/
https://www.ncbi.nlm.nih.gov/pubmed/35153806
http://dx.doi.org/10.3389/fphys.2021.730127

Ejemplares similares